A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm
Previous randomized controlled trials (RCTs) investigating Botulinum toxin A (BoNT-A) for treatment of hemifacial spasm (HFS) have primarily focused on symptom relief and quality-of-life improvement. However, head-to-head comparisons of different BoNT-A formulations, particularly in terms of onset,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/17/4/173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155073834844160 |
|---|---|
| author | Subsai Kongsaengdao Arkhom Arayawichanont Kanoksri Samintharapanya Pichai Rojanapitayakorn Benchalak Maneeton Narong Maneeton |
| author_facet | Subsai Kongsaengdao Arkhom Arayawichanont Kanoksri Samintharapanya Pichai Rojanapitayakorn Benchalak Maneeton Narong Maneeton |
| author_sort | Subsai Kongsaengdao |
| collection | DOAJ |
| description | Previous randomized controlled trials (RCTs) investigating Botulinum toxin A (BoNT-A) for treatment of hemifacial spasm (HFS) have primarily focused on symptom relief and quality-of-life improvement. However, head-to-head comparisons of different BoNT-A formulations, particularly in terms of onset, duration of action, and efficacy, remain limited. We conducted a 12-week prospective, randomized controlled trial comparing the efficacy and safety of 33.33 units of Neubotulinum toxin A (Neu-BoNT-A) with 100 units of Abobotulinum toxin A (Abo-BoNT-A) in the treatment of HFS. A total of 87 patients were enrolled between September and December 2024. Neu-BoNT-A and Abo-BoNT-A exhibited similar onset and duration of action [5.0 ± 0.9 vs. 6.2 ± 0.7 days, respectively (<i>p</i> = 0.33)]. After 12 weeks of treatment, Neu-BoNT-A demonstrated superior efficacy in reducing the daily duration of HFS (2.00 ± 0.06 vs. 1.42 ± 0.10 h/day, <i>p</i> < 0.001) and improving sleep duration (1.37 ± 0.01 vs. 1.06 ± 0.01 h/day, <i>p</i> < 0.001). However, Abo-BoNT-A was associated with significantly lower absolute daily disability time compared to Neu-BoNT-A (11.4 vs. 1.2 min/day, <i>p</i> < 0.001). No serious adverse events were observed. Both Neu-BoNT-A and Abo-BoNT-A were safe and effective in treating HFS. However, Neu-BoNT-A was more effective in HFS with minimal symptoms without disability and Abo-BoNT-A more effective in HFS with greater duration of disability. |
| format | Article |
| id | doaj-art-b4cbd0fa293f491395dd80b246b01923 |
| institution | OA Journals |
| issn | 2072-6651 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj-art-b4cbd0fa293f491395dd80b246b019232025-08-20T02:25:03ZengMDPI AGToxins2072-66512025-04-0117417310.3390/toxins17040173A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial SpasmSubsai Kongsaengdao0Arkhom Arayawichanont1Kanoksri Samintharapanya2Pichai Rojanapitayakorn3Benchalak Maneeton4Narong Maneeton5Office of Senior Advisor, Department of Medical Services, Ministry of Public Health, Nonthaburi 11000, ThailandDivision of Neurology, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani 34000, ThailandDivision of Neurology, Department of Medicine Lampang Hospital, Lampang 52000, ThailandDivision of Neurology, Department of Medicine Suratthani Hospital, Suratthani 84000, ThailandDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandPrevious randomized controlled trials (RCTs) investigating Botulinum toxin A (BoNT-A) for treatment of hemifacial spasm (HFS) have primarily focused on symptom relief and quality-of-life improvement. However, head-to-head comparisons of different BoNT-A formulations, particularly in terms of onset, duration of action, and efficacy, remain limited. We conducted a 12-week prospective, randomized controlled trial comparing the efficacy and safety of 33.33 units of Neubotulinum toxin A (Neu-BoNT-A) with 100 units of Abobotulinum toxin A (Abo-BoNT-A) in the treatment of HFS. A total of 87 patients were enrolled between September and December 2024. Neu-BoNT-A and Abo-BoNT-A exhibited similar onset and duration of action [5.0 ± 0.9 vs. 6.2 ± 0.7 days, respectively (<i>p</i> = 0.33)]. After 12 weeks of treatment, Neu-BoNT-A demonstrated superior efficacy in reducing the daily duration of HFS (2.00 ± 0.06 vs. 1.42 ± 0.10 h/day, <i>p</i> < 0.001) and improving sleep duration (1.37 ± 0.01 vs. 1.06 ± 0.01 h/day, <i>p</i> < 0.001). However, Abo-BoNT-A was associated with significantly lower absolute daily disability time compared to Neu-BoNT-A (11.4 vs. 1.2 min/day, <i>p</i> < 0.001). No serious adverse events were observed. Both Neu-BoNT-A and Abo-BoNT-A were safe and effective in treating HFS. However, Neu-BoNT-A was more effective in HFS with minimal symptoms without disability and Abo-BoNT-A more effective in HFS with greater duration of disability.https://www.mdpi.com/2072-6651/17/4/173hemifacial spasmbotulinum Toxin Aquality of lifesleep qualitydepression |
| spellingShingle | Subsai Kongsaengdao Arkhom Arayawichanont Kanoksri Samintharapanya Pichai Rojanapitayakorn Benchalak Maneeton Narong Maneeton A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm Toxins hemifacial spasm botulinum Toxin A quality of life sleep quality depression |
| title | A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm |
| title_full | A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm |
| title_fullStr | A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm |
| title_full_unstemmed | A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm |
| title_short | A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport<sup>®</sup>) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox<sup>®</sup>) for the Treatment of Hemifacial Spasm |
| title_sort | 12 week prospective double blind multicenter randomized study comparing 100 units of abobotulinum toxin type a dysport sup r sup and 33 33 units of neubotulinum toxin type a neuronox sup r sup for the treatment of hemifacial spasm |
| topic | hemifacial spasm botulinum Toxin A quality of life sleep quality depression |
| url | https://www.mdpi.com/2072-6651/17/4/173 |
| work_keys_str_mv | AT subsaikongsaengdao a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT arkhomarayawichanont a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT kanoksrisamintharapanya a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT pichairojanapitayakorn a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT benchalakmaneeton a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT narongmaneeton a12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT subsaikongsaengdao 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT arkhomarayawichanont 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT kanoksrisamintharapanya 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT pichairojanapitayakorn 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT benchalakmaneeton 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm AT narongmaneeton 12weekprospectivedoubleblindmulticenterrandomizedstudycomparing100unitsofabobotulinumtoxintypeadysportsupsupand3333unitsofneubotulinumtoxintypeaneuronoxsupsupforthetreatmentofhemifacialspasm |